Solving the 'Goldilocks problem' in dementia clinical trials with multimodal AI

Area of Science:

• Neuroscience
• Medical Informatics
• Artificial Intelligence

Background:

• Alzheimer's Disease and related dementias (ADRD) therapeutics development faces challenges due to patient heterogeneity and diagnostic limitations.
• Current clinical trial designs struggle to select patients who will benefit from novel treatments, impacting success rates.

Purpose of the Study:

• To explore how Artificial Intelligence (AI), specifically multimodal machine learning, can address patient stratification challenges in ADRD.
• To demonstrate AI's potential in optimizing clinical trial patient selection and enabling precision treatment in real-world settings.

Main Methods:

• Examined the conceptual framework for identifying dementia stage and subtype.
• Reviewed data from Alzheimer's disease therapeutic clinical trials.
• Discussed the integration of AI into clinical workflows, model interpretability, generalizability, and ethical considerations.

Main Results:

• AI-guided patient stratification can significantly improve clinical trial outcomes by ensuring appropriate patient inclusion.
• AI can reduce trial costs and enhance patient recruitment efficiency.
• Intelligent analytics, combined with scientific and clinical expertise, can accelerate diagnostic and therapeutic discovery.

Conclusions:

• AI offers a powerful solution to the 'Goldilocks problem' in clinical trials, enabling precision medicine for ADRD.
• Integrating AI into healthcare workflows is crucial for transforming dementia care and improving patient outcomes globally.
• Addressing algorithmic bias and ensuring model generalizability are critical for the ethical and effective deployment of AI in dementia treatment.